(Q37225817)

19 August 2017

In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis (English)

1 reference

19 August 2017

0 references

visceral leishmaniasis

1 reference

1 reference

Leishmania donovani

1 reference

Smriti Sharma

2

0 references

Manu Vanaerschot

object named as

Manu Vanaerschot

6

0 references

Poonam Salotra

object named as

Poonam Salotra

5

0 references

Shyam Sundar

8

object named as

Shyam Sundar

1 reference

19 August 2017

Vijay Kumar Prajapati

1

1 reference

19 August 2017

Madhukar Rai

3

1 reference

19 August 2017

Bart Ostyn

4

1 reference

19 August 2017

Jean-Claude Dujardin

7

1 reference

19 August 2017

language of work or name

English

0 references

publication date

26 August 2013

1 reference

American Journal of Tropical Medicine and Hygiene

19 August 2017

1 reference

19 August 2017

89

1 reference

19 August 2017

4

1 reference

19 August 2017

750-754

1 reference

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

Leishmaniasis worldwide and global estimates of its incidence

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

Evaluation of blood agar microtiter plates for culturing leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

Can visceral leishmaniasis be eliminated from Asia?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

Oral miltefosine for Indian visceral leishmaniasis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3795107

Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use

26 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23980130

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4269/AJTMH.13-0096

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

23980130

1 reference